Exelixis, Inc. 10-Q Filing Summary
Business Context and Reporting Period
Company: Exelixis, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: Exelixis is a biotechnology company focused on discovering and developing small molecule therapeutics for cancer and other serious diseases. The company generates revenue primarily through strategic collaborations, licensing agreements, and research funding rather than product sales, as it has no approved pharmaceutical products. Key partners include Bristol-Myers Squibb, Sankyo, Helsinn Healthcare, and Symphony Evolution, Inc. (SEI).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2005 |
|---|---|---|---|
| Total Revenues | $23,540 | $68,899 | $61,584 |
| Net Loss | $(25,197) | $(76,310) | $(59,882) |
| Net Loss Per Share (Basic/Diluted) | $(0.30) | $(0.91) | $(0.77) |
| Cash and Cash Equivalents (Sep 30, 2006) | $55,700 | Total Liquidity (Cash, Marketable Securities, SEI Investments): $154.4 million | |
| Total Assets | $270,657 | ||
| Total Liabilities | $245,321 | Includes $94.3 million in convertible promissory loans and notes payable. | |
| Stockholders' Equity (Deficit) | $(19,598) |
Cash Flow (Nine Months Ended Sep 30, 2006):
- Net cash used in operating activities: $(55,463) thousand
- Net cash provided by investing activities: $22,337 thousand
- Net cash provided by financing activities: $7,429 thousand
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 63% for the three months and 12% for the nine months compared to the prior year. This was driven by new collaborations with Bristol-Myers Squibb and Sankyo, and a $4.0 million milestone payment from Helsinn Healthcare.
- Expense Increases: Research and Development (R&D) expenses rose 31% (quarterly) and 27% (year-to-date) due to expanded clinical trials (Phase 1, 2, and 3) and the adoption of SFAS 123R, which significantly increased stock-based compensation expense.
- Net Loss Expansion: The net loss widened to $76.3 million for the nine months ended September 30, 2006, compared to $59.9 million in the prior year period, primarily due to higher operating expenses and the impact of SFAS 123R.
- Debt Repayment: The company repaid a $30.0 million convertible promissory note to PDL BioPharma in May 2006, reducing interest expense.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Liquidity: Management anticipates that current cash, marketable securities, and expected funding from collaborators will sustain operations for at least 12 months following the filing date. However, the company expects to incur substantial losses for the foreseeable future and will require additional funding to support its aggressive development pipeline and meet financial covenants.
Recent Developments:
- XL999 Suspension: In November 2006, Exelixis suspended enrollment in the XL999 clinical trial program following a preliminary review showing an apparent increase in serious adverse cardiovascular events.
- Capital Raise: In October 2006 (subsequent to the period end), the company completed a public offering of 11.5 million shares, raising approximately $90.5 million in net proceeds.
Key Risks and Contingencies:
- Financial Covenants: The company must maintain working capital of at least $25.0 million and cash/investments of at least $50.0 million to comply with its loan agreement with GlaxoSmithKline. Failure to comply could trigger immediate repayment of outstanding obligations.
- SEI Repurchase Options: Exelixis licensed three key compounds (XL647, XL999, XL784) to Symphony Evolution, Inc. (SEI) for $80 million. Exelixis retains options to repurchase these assets, but exercising these options requires significant capital. If GlaxoSmithKline selects these compounds for development, Exelixis must repurchase them from SEI, potentially creating a cash shortfall if milestone payments are insufficient.
- Clinical Uncertainty: The suspension of the XL999 trial and the inherent risks of clinical development pose significant threats to future revenue milestones and regulatory approval.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $90.5 million October 2006 capital raise combined with existing cash to meet the $25 million working capital and $50 million cash/investment covenants with GlaxoSmithKline.
- XL999 Status: Monitor the outcome of the safety review regarding the suspended XL999 trial, as this asset is critical to the SEI financing structure and potential GlaxoSmithKline milestones.
- SEI Repurchase Obligations: Assess the financial impact of potential repurchase options for XL647, XL999, and XL784 from SEI, particularly if GlaxoSmithKline exercises its selection rights.
- Stock-Based Compensation: Review the ongoing impact of SFAS 123R adoption on future operating expenses and net loss.
- Collaboration Milestones: Track the progress of the Bristol-Myers Squibb (LXR) and Sankyo (MR) collaborations, which are key drivers of near-term revenue recognition.